18F-fluorodeoxyglucose Positron Emission Tomography Influences Management Decisions in Patients with Biliary Cancer

Journal of the American College of Surgeons

Volumn 206, Issue 1, 2008, Pages 57-65

  Corvera, Carlos U ^a   Blumgart, Leslie H ^a   Akhurst, Timothy ^a   DeMatteo, Ronald P ^a   D'Angelica, Michael ^a   Fong, Yuman ^a   Jarnagin, William Robert ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC IMAGING; DISEASE COURSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SENSITIVITY ANALYSIS; ADULT; AGED; BILE DUCT TUMOR; CHOLECYSTECTOMY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GALLBLADDER TUMOR; INTRAHEPATIC BILE DUCT; MALE; METHODOLOGY; MIDDLE AGED; PROGNOSIS; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLECYSTECTOMY; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 37249057824     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.07.002     Document Type: Article

References (21)

1. Jarnagin W.R., Klimstra D.S., Hezel M., et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24 (2006) 1152-1160
2. Jarnagin W.R., Fong Y., DeMatteo R.P., et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234 (2001) 507-517 discussion 517-519
3. Ouchi K., Sugawara T., Ono H., et al. Diagnostic capability and rational resectional surgery for early gallbladder cancer. Hepatogastroenterol 46 (1999) 1557-1560
4. Fong Y., Jarnagin W., and Blumgart L.H. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg 232 (2000) 557-566
5. Matsumoto Y., Fujii H., Aoyama H., et al. Surgical treatment of primary carcinoma of the gallbladder based on the histologic analysis of 48 surgical specimens. Am J Surg 163 (1992) 239-245
6. Muratore A., Polastri R., and Capussotti L. Radical surgery for gallbladder cancer: current options. Eur J Surg Oncol 26 (2000) 438-443
7. Nimura Y., Hayakawa N., Kamiya J., et al. Hepatopancreatoduodenectomy for advanced carcinoma of the biliary tract. Hepatogastroenterology 38 (1991) 170-175
8. Shirai Y., Ohtani T., Tsukada K., and Hatakeyama K. Pancreaticoduodenectomy for gallbladder cancer with peripancreatic nodal metastases. Hepatogastroenterology 44 (1997) 376-377
9. Bartlett D.L., Fong Y.M., Fortner J.G., et al. Long-term results after resection for gallbladder cancer-implications for staging and management. Ann Surg 224 (1996) 639-646
10. Akhurst T., and Fong Y. Positron emission tomography in surgical oncology. Adv Surg 36 (2002) 309-331
11. Reske S.N., Bares R., Bull U., et al. [Clinical value of positron emission tomography (PET) in oncologic questions: results of an interdisciplinary consensus conference]. Schirmerreschaft der deutschen gesellschaft for nuklearmedizin klinische wertigkeit der positronen-emissions-tomographie (PET) bei onkologischen fragestellungen: ergebnisse einer interdisziplinaren konsensuskonferenz. Nuklearmedizin 35 (1996) 42-52
12. Anderson C.D., Rice M.H., Pinson C.W., et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8 (2004) 90-97
13. Kim Y.J., Yun M., Lee W.J., et al. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 30 (2003) 1467-1472
14. Burke E.C., Jarnagin W.R., Hochwald S.N., et al. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228 (1998) 385-394
15. Fritscher-Ravens A., Bohuslavizki K.H., Broering D.C., et al. FDG-PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 22 (2001) 1277-1285
16. Kato T., Tsukamoto E., Kuge Y., et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 29 (2002) 1047-1054
17. Keiding S., Hansen S.B., Rasmussen H.H., et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 28 (1998) 700-706
18. Kluge R., Schmidt F., Caca K., et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 33 (2001) 1029-1035
19. Koh T., Taniguchi H., Yamaguchi A., et al. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol 84 (2003) 74-81
20. Widjaja A., Mix H., Wagner S., et al. Positron emission tomography and cholangiocarcinoma in primary sclerosing cholangitis. J Gastroenterol 37 (1999) 731-733
21. Rea D.J., Munoz-Juarez M., Farnell M.B., et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 139 (2004) 514-523 discussion 523-525